Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 4;5(1):2.
doi: 10.3390/antib5010002.

Autoantibodies in SLE: Specificities, Isotypes and Receptors

Affiliations
Review

Autoantibodies in SLE: Specificities, Isotypes and Receptors

Barbara Dema et al. Antibodies (Basel). .

Abstract

Systemic Lupus Erythematosus (SLE) is characterized by a wide spectrum of auto-antibodies which recognize several cellular components. The production of these self-reactive antibodies fluctuates during the course of the disease and the involvement of different antibody-secreting cell populations are considered highly relevant for the disease pathogenesis. These cells are developed and stimulated through different ways leading to the secretion of a variety of isotypes, affinities and idiotypes. Each of them has a particular mechanism of action binding to a specific antigen and recognized by distinct receptors. The effector responses triggered lead to a chronic tissue inflammation. DsDNA autoantibodies are the most studied as well as the first in being characterized for its pathogenic role in Lupus nephritis. However, others are of growing interest since they have been associated with other organ-specific damage, such as anti-NMDAR antibodies in neuropsychiatric clinical manifestations or anti-β2GP1 antibodies in vascular symptomatology. In this review, we describe the different auto-antibodies reported to be involved in SLE. How autoantibody isotypes and affinity-binding to their antigen might result in different pathogenic responses is also discussed.

Keywords: Fc receptors; SLE; autoantibodies; isotypes; lupus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Tan E.M. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 1989;44:93–151. - PubMed
    1. Conrad K., Roggenbuck D., Reinhold D., Sack U. Autoantibody diagnostics in clinical practice. Autoimmun. Rev. 2012;11:207–211. doi: 10.1016/j.autrev.2011.05.014. - DOI - PubMed
    1. Li J., Leng X., Li Z., Ye Z., Li C., Li X., Zhu P., Wang Z., Zheng Y., Li X., et al. Chinese SLE treatment and research group registry: III. Association of autoantibodies with clinical manifestations in chinese patients with systemic lupus erythematosus. J. Immunol. Res. 2014;2014:809389. doi: 10.1155/2014/809389. - DOI - PMC - PubMed
    1. Yaniv G., Twig G., Shor D.B., Furer A., Sherer Y., Mozes O., Komisar O., Slonimsky E., Klang E., Lotan E., et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: A diversity of 180 different antibodies found in SLE patients. Autoimmun. Rev. 2015;14:75–79. doi: 10.1016/j.autrev.2014.10.003. - DOI - PubMed
    1. Dema B., Charles N. Advances in mechanisms of systemic lupus erythematosus. Discov. Med. 2014;17:247–255. - PubMed

LinkOut - more resources